Abstract CT337: Phase I/Ib Study of the PARP Inhibitor (parpi) Olaparib (O) with Carboplatin (C) in Triple Negative Breast Cancer (TNBC) at Low Genetic Risk (NCT00647062)
Cancer research（2014）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined